Involvement of Dietary Bioactive Proteins and Peptides in Autism Spectrum Disorders

Current Protein and Peptide Science

Volumn 14, Issue 8, 2013, Pages 674-679

  Siniscalco, Dario ^a,b,c   Antonucci, Nicola ^d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Centre for Autism La Forza del Silenzio   (Italy)

^c Cancellautismo no profit association for autism care   (Italy)

^d Biomedical Centre for Autism Research and Treatment   (Italy)

Author keywords

Autism; Bioactive peptides; Dietary proteins

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ALANINE; CARNITINE; CASEIN; CD69 ANTIGEN; CHOLINESTERASE INHIBITOR; DIETARY BIOACTIVE PEPTIDE; DIETARY BIOACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE; GLUTEN; LACTOFERRIN; LACTOPEROXIDASE; LYMPHOCYTE RECEPTOR; MECOBALAMIN; MELATONIN; MILK PROTEIN; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OXYTOCIN; PEPTIDES AND PROTEINS; PROLINE RICH PROTEIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUPUNCTURE; AUTISM; BLOOD BRAIN BARRIER; CANDIDA; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; FUNGAL COLONIZATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBARIC OXYGEN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE MUCOSA PERMEABILITY; METHYLATION; MUSIC THERAPY; NEUROTRANSMISSION; OXIDATIVE STRESS; PROTEIN INTAKE; PSYCHOTHERAPY; REVIEW; VISION THERAPY;

ANIMALS; AUTISTIC DISORDER; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DIETARY PROTEINS; HUMANS; PEPTIDES;

EID: 84891822510     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203711209070602     Document Type: Review

References (79)

1. Siniscalco, D.; Bradstreet, J.J.; Antonucci, N. The Promise of Regenerative Medicine and Stem Cell Research for the Treatment of Autism. J. Regen. Med., 2012, 1, 1.
2. Toro, R.; Konyukh, M.; Delorme, R.; Leblond, C.; Chaste, P.; Fauchereau, F.; Coleman, M.; Leboyer, M.; Gillberg, C.; Bourgeron, T. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet., 2010, 26, 363-372.
3. Herbert, M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr. Opin. Neurol., 2010, 23, 103-110.
4. Stanković, M.; Lakić, A.; Ilić, N. Autism and autistic spectrum disorders in the context of new DSM-V classification, and clinical and epidemiological data. Srp. Arh. Celok. Lek., 2012, 140 (3-4), 236-243.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, 4th ed.; Washington, DC, 2000.
6. Siniscalco, D.; Sapone, A.; Cirillo, A.; Giordano, C.; Maione, S.; Antonucci, N. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future? J. Biomed. Biotechnol., 2012, 2012, 480289.
7. Baio, J. Prevalence of Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. CDC Surveillance Summaries., 2012, 61 (SS03), 1-19.
8. Chadman, K.K.; Guariglia, S.R.; Yoo, J.H. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin. Drug Discov., 2012, 7 (5), 407-416.
9. Hampson, D.R.; Gholizadeh, S.; Pacey, L.K. Pathways to drug development for autism spectrum disorders. Clin. Pharmacol. Ther., 2012, 91 (2), 189-200.
10. McCracken, J.T. Safety issues with drug therapies for autism spectrum disorders. J. Clin. Psychiatry., 2005, 66, 32-37.
11. Tandon, M.; Pruett, J.R. Jr. An overview of the use of antidepressants in children and adolescents. Mol. Med., 2008, 105, 79-84.
12. Nevels, R.M.; Dehon, E.E.; Alexander, K.; Gontkovsky, S.T. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp. Clin. Psychopharmacol., 2010, 18, 184-201.
13. Rossignol, D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann. Clin. Psychiatry., 2009, 21 (4), 213-236.
14. Senel, H.G. Parents' views and experiences about complementary and alternative medicine treatments for their children with autistic spectrum disorder. J. Autism. Dev. Disord., 2010, 40, 494-503.
15. Wong, V.C.; Sun, J.G. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. J. Altern. Complement. Med., 2010, 16, 545-553.
16. Filipek, P.A.; Steinberg-Epstein, R.; Book, T.M. Intervention for autistic spectrum disorders. Neuro. Rx. 2006, 3, 207-216.
17. Vismara, L.A.; Rogers, S.J. Behavioral treatments in autism spectrum disorder: what do we know? Annu. Rev. Clin. Psychol., 2010, 6, 447-468.
18. Kasari, C.; Lawton, K. New directions in behavioral treatment of autism spectrum disorders. Curr. Opin. Neurol., 2010, 23, 137-143.
19. Jahan-Mihan, A.; Luhovyy, B.L.; El Khoury, D.; Anderson, G.H. Dietary proteins as determinants of metabolic and physiologic functions of the gastrointestinal tract. Nutrients, 2011, 3 (5), 574-603.
20. Chou, C.J.; Affolter, M.; Kussmann, M. A nutrigenomics view of protein intake: macronutrient, bioactive peptides, and protein turnover. Prog. Mol. Biol. Transl. Sci., 2012, 108, 51-74.
21. Walther, B.; Sieber, R. Bioactive proteins and peptides in foods. Int. J. Vitam. Nutr. Res., 2011, 81, 181-192.
22. Möller, N.P.; Scholz-Ahrens, K.E.; Roos, N.; Schrezenmeir, J. Bioactive peptides and proteins from foods: indication for health effects. Eur. J. Nutr., 2008, 47 (4), 171-182.
23. Udenigwe, C.C.; Aluko, R.E. Food protein-derived bioactive peptides: production, processing, and potential health benefits. J. Food Sci., 2012, 77 (1), R11-24.
24. Rutherfurd-Markwick, K.J.; Moughan, P.J. Bioactive peptides derived from food. J. AOAC. Int. 2005, 88 (3), 955-966.
25. Meisel, H. Biochemical properties of regulatory peptides derived from milk proteins. Biopolymers, 1997, 43 (2), 119-128.
26. Tidona, F.; Criscione, A.; Guastella, A.M.; Zuccaro, A.; Bordonaro, S.; Marletta, D. Bioactive peptides in dairy products. Ital. J. Anim. Sci., 2009, 8, 315-340.
27. Pihlanto, A.; Korhonen, H. Bioactive peptides and proteins. Adv. Food Nutr. Res., 2003, 47, 175-276.
28. Agyei, D.; Danquah, M.K. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnol. Adv., 2011, 29 (3), 272-277.
29. Zambrowicz, A.; Timmer, M.; Polanowski, A.; Lubec, G.; Trziszka, T. Manufacturing of peptides exhibiting biological activity. Amino Acids., 2012, in press.
30. Bazinet, L.; Firdaous, L. Membrane processes and devices for separation of bioactive peptides. Recent Pat. Biotechnol., 2009, 3 (1), 61-72.
31. Buie, T.; Campbell, D.B.; Fuchs, G.J. 3rd.; Furuta, G.T.; Levy, J.; Vandewater, J.; Whitaker, A.H.; Atkins, D.; Bauman, M.L.; Beaudet, A.L.; Carr, E.G.; Gershon, M.D.; Hyman, S.L.; Jirapinyo, P.; Jyonouchi, H.; Kooros, K.; Kushak, R.; Levitt, P.; Levy, S.E.; Lewis, J.D.; Murray, K.F.; Natowicz, M.R.; Sabra, A.; Wershil, B.K.; Weston, S.C.; Zeltzer, L.; Winter, H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 2010, 125 Suppl 1, S1-18.
32. Kral, T.V.; Eriksen, W.T.; Souders, M.C.; Pinto-Martin, J.A. Eating Behaviors, Diet Quality, and Gastrointestinal Symptoms in Children With Autism Spectrum Disorders: A Brief Review. J. Pediatr. Nurs., 2013, S0882-5963 (13) 00096-1.
33. Reichelt, K.L.; Knivsberg, A.M. The possibility and probability of a gut-to-brain connection in autism. Ann. Clin. Psychiatry., 2009, 21 (4), 205-211.
34. Theoharides, T.C.; Doyle, R. Autism, gut-blood-brain barrier, and mast cells. J. Clin. Psychopharmacol., 2008, 28 (5), 479-483.
35. de Theije, C.G.; Wu, J.; da Silva, S.L.; Kamphuis, P.J.; Garssen, J.; Korte, S.M.; Kraneveld, A.D. Pathways underlying the gut-tobrain connection in autism spectrum disorders as future targets for disease management. Eur. J. Pharmacol., 2011, 668 Suppl 1, S70-S80.
36. de Magistris, L.; Familiari, V.; Pascotto, A.; Sapone, A.; Frolli, A.; Iardino, P.; Carteni, M.; De Rosa, M.; Francavilla, R.; Riegler, G.; Militerni, R.; Bravaccio, C. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J. Pediatr. Gastroenterol. Nutr., 2010, 51 (4), 418-424.
37. Souza, N.C.; Mendonca, J.N.; Portari, G.V.; Jordao, Junior A. A; Marchini, J.S.; Chiarello, P.G. Intestinal permeability and nutritional status in developmental disorders. Altern. Ther. Health Med., 2012, 18 (2), 19-24.
38. Onore, C.; Careaga, M.; Ashwood, P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav. Immun., 2012, 26 (3), 383-392.
39. Gupta, S., Samra, D., Agrawal, S. Adaptive and innate immune responses in Autism: Rationale for therapeutic use of intravenous immunoglobulin. J. Clin. Immunol., 2010, 30, S90-S96.
40. Siniscalco, D.; Sapone, A.; Giordano, C.; Cirillo, A.; de Novellis, V.; de Magistris, L.; Rossi, F.; Fasano, A.; Maione, S.; Antonucci, N. The Expression of Caspases is Enhanced in Peripheral Blood Mononuclear Cells of Autism Spectrum Disorder Patients. J. Autism Dev. Disord., 2012, 42 (7), 1403-1410.
41. Jyonouchi, H.; Sun, S.; Itokazu, N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology, 2002, 46 (2), 76-84.
42. Vojdani, A.; Pangborn, J.B.; Vojdani, E.; Cooper, E.L. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int. J. Immunopathol. Pharmacol., 2003, 16 (3), 189-199.
43. Garvey, J. Diet in autism and associated disorders. J. Fam. Health Care, 2002, 12 (2), 34-38.
44. Shattock, P.; Whiteley, P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin. Ther. Targets, 2002, 6 (2), 175-183.
45. Jass, J.R. The intestinal lesion of autistic spectrum disorder. Eur. J. Gastroenterol. Hepatol., 2005, 17 (8), 821-822.
46. Cass, H.; Gringras, P.; March, J.; McKendrick, I.; O'Hare, A.E.; Owen, L.; Pollin, C. Absence of urinary opioid peptides in children with autism. Arch. Dis. Child, 2008, 93 (9), 745-750.
47. Hunter, L.C.; O'Hare, A.; Herron, W.J.; Fisher, L.A.; Jones, G.E. Opioid peptides and dipeptidyl peptidase in autism. Dev. Med. Child Neurol., 2003, 45 (2), 121-128.
48. Dettmer, K.; Hanna, D.; Whetstone, P.; Hansen, R.; Hammock, B.D. Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. Anal. Bioanal. Chem., 2007, 388 (8), 1643-1651.
49. Knivsberg, A.M.; Reichelt, K.L.; Høien, T.; Nødland, M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr. Neurosci., 2002, 5 (4), 251-261.
50. Millward, C.; Ferriter, M.; Calver, S.; Connell-Jones, G. Glutenand casein-free diets for autistic spectrum disorder. Cochrane Database Syst. Rev., 2004, 2, CD003498.
51. Knivsber, A.M.; Reichelt, K.L.; Nødland, M. Reports on dietary intervention in autistic disorders. Nutr. Neurosci., 2001, 4 (1), 25-37.
52. Kidd, P.M. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern. Med. Rev., 2002, 7 (6), 472-499.
53. Siniscalco, D.; Antonucci, N. Possible use of Trichurissuis ova in autism spectrum disorders therapy. Med. Hypotheses., 2013, 81 (1), 1-4.
54. Burrus, C.J. A biochemical rationale for the interaction between gastrointestinal yeast and autism. Med. Hypotheses., 2012, 79 (6), 784-785.
55. Vogel, H.J. Lactoferrin, a bird's eye view. Biochem. Cell Biol., 2012, 90 (3), 233-244.
56. Legrand, D. Lactoferrin, a key molecule in immune and inflammatory processes. Biochem. Cell Biol., 2012, 90 (3), 252-268.
57. Puddu, P.; Valenti, P.; Gessani, S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie., 2009, 91 (1), 11-18.
58. Legrand, D.; Pierce, A.; Elass, E.; Carpentier, M.; Mariller, C.; Mazurier, J. Lactoferrin structure and functions. Adv. Exp. Med. Biol., 2008, 606, 163-194.
59. Shaw, W. Biological treatments for autism and PDD. 3rd edition. 2008.
60. Ghibaudi, E.; Laurenti, E. Unraveling the catalytic mechanism of lactoperoxidase and myeloperoxidase. Eur. J. Biochem., 2003, 270 (22), 4403-4412.
61. Lönnerdal, B. Nutritional and physiologic significance of human milk proteins. Am. J. Clin. Nutr., 2003, 77 (6), 1537S-1543S.
62. Janusz, M.; Lisowski, J. Proline-rich polypeptide (PRP)-an immunomodulatory peptide from ovine colostrum. Arch. Immunol. Ther. Exp. (Warsz), 1993, 41 (5-6), 275-279.
63. Zimecki, M.; Artym, J. Therapeutic properties of proteins and peptides from colostrum and milk. Postepy. Hig. Med. Dosw. (Online), 2005, 59, 309-323.
64. Yenkoyan, K.; Safaryan, K.; Chavushyan, V.; Meliksetyan, I.; Navasardyan, G.; Sarkissian, J.; Galoyan, A.; Aghajanov, M. Neuroprotective action of proline-rich polypeptide-1 in β-amyloid induced neurodegeneration in rats. Brain Res. Bull., 2011, 86 (3-4), 262-271.
65. Séverin, S.; Wenshui, X. Milk biologically active components as nutraceuticals: review. Crit. Rev. Food Sci. Nutr., 2005, 45 (7-8), 645-656.
66. Maher, P. Methylglyoxal, advanced glycation end products and autism: is there a connection? Med. Hypotheses., 2012, 78 (4), 548-552.
67. Melnyk, S.; Fuchs, G.J.; Schulz, E.; Lopez, M.; Kahler, S.G.; Fussell, J.J.; Bellando, J.; Pavliv, O.; Rose, S.; Seidel, L.; Gaylor, D.W.; James, S.J. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J. Autism Dev. Disord., 2012, 42 (3), 367-377.
68. Geier, D.A.; Kern, J.K.; Garver, C.R.; Adams, J.B.; Audhya, T.; Geier, M.R. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem. Res., 2009, 34 (2), 386-393.
69. Bowers, K.; Li, Q.; Bressler, J.; Avramopoulos, D.; Newschaffer, C.; Fallin, M.D. Glutathione pathway gene variation and risk of autism spectrum disorders. J. Neurodev. Disord., 2011, 3 (2), 132-143.
70. Kern, J.K.; Geier, D.A.; Adams, J.B.; Garver, C.R.; Audhya, T.; Geier, M.R. A clinical trial of glutathione supplementation in autism spectrum disorders. Med. Sci. Monit., 2011, 17 (12), CR677-CR682.
71. Witschi, A.; Reddy, S.; Stofer, B.; Lauterburg, B.H. The systemic availability of oral glutathione. Eur. J. Clin. Pharmacol., 1992, 43 (6), 667-669.
72. McPherson, R.A.; Hardy, G. Clinical and nutritional benefits of cysteine-enriched protein supplements. Curr. Opin. Clin. Nutr. Metab. Care., 2011, 14 (6), 562-568.
73. James, S.J.; Melnyk, S.; Fuchs, G.; Reid, T.; Jernigan, S.; Pavliv, O.; Hubanks, A.; Gaylor, D.W. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am. J. Clin. Nutr., 2009, 89 (1), 425-430.
74. McGinnis, W.R. Oxidative stress in autism. Altern. Ther. Health Med., 2004, 10 (6), 22-36.
75. Mostafa, G.A.; El-Hadidi, E.S.; Hewedi, D.H.; Abdou, M.M. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J. Neuroimmunol., 2010, 219 (1-2), 114-118.
76. Siniscalco, D. Stem Cell Research: An Opportunity for Autism Spectrum Disorders Treatment. Autism. 2012, 2: e106.
77. Hunsinger, D.M.; Nguyen, T.; Zebraski, S.E.; Raffa, R.B. Is there a basis for novel pharmacotherapy of autism? Life Sci. 2000, 67 (14), 1667-1682.
78. Sarmadi, B.H.; Ismail, A. Antioxidative peptides from food proteins: a review. Peptides. 2010, 31 (10), 1949-1956.
79. Kitts, D.D.; Weiler, K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr. Pharm. Des., 2003, 9 (16), 1309-1323.